Copyright © 2007, European Society of Cardiology
Tenascin-C: A key molecule in graft stenosis
Molekulare Pharmakologie, Isntitut für Pharmakologie und Klinische Pharmakologie, Universitätsklinikum Düsseldorf
* Tel.: +49 211 81 12513x12500; fax: +49 211 81 14781. Email address: jens.fischer@uni-duesseldorf.de
Received 26 March 2007; accepted 2 April 2007
| The first 10% of the full text of this article appears below. |
See article by Sawada et al. [3] (366–376) in this issue.
Coronary artery bypass grafting (CABG) using venous and arterial grafts is a standard surgical procedure for the treatment of advanced coronary artery disease. However graft failure is common especially after transplantation of saphenous vein grafts, the first vessels used in CABG [1]. After one year up to 15% and after 10 years up to 50% of saphenous vein grafts are severely affected by neointimal thickening and advanced atherosclerosis. Improved long-term patency and survival in treatment of advanced coronary artery disease has been achieved by the use of arterial grafts from the left internal